Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3

H. H. Van Ravenswaay Claasen, R. J. Van De Griend, D. Mezzanzanica, R. L H Bolhuis, S. O. Warnaar, G. J. Fleuren

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OV-TL 3 and MOv 18 MAbs, due to their restricted specificity, have been successfully used to visualize ovarian cancer in patients and might therefore be used to develop therapies for ovarian cancer. The bi-specific MAbs αT3/OC2 and αOC/TR (both being combinations of MOv 18 and αCD3) have been shown to lyse ovarian tumor cells in vitro. To evaluate the relative merits of MOv 18/CD3 and OV-TL 3/CD3, the present study was undertaken in which the bi-specific MAbs αT3/OC2 and αOC/TR, and a newly developed bi-specific MAb, OV-TL 3/CD3, were highly purified and compared for specificity, stability, purification and cytolytic potential. The dual specificity of the hybrid-hybridoma supernatants was analyzed by immunohistochemistry, and by testing bi-specific MAb-mediated cytotoxicity against relevant target cells in the presence of effector cells. Stability testing of bi-specific MAb-producing hybridhybridomas showed that, after sub-cloning, clones stably produced up to 40% bi-specific MAb even after prolonged in vitro culture. The purification of the bi-specific fractions was performed with protein A and by ion-exchange high-pressure liquid chromatography, depending on the sub-class combination of the bi-specific MAb. The purified bi-specific MAbs were tested for their ability to mediate target-cell lysis with the use of cytotoxic T-cell clones and activated peripheral-blood lymphocytes. The purified αT3/OC2, αOC/TR, and OV-TL 3/CD3 were all able to mediate highly specific lysis of various ovarian-carcinoma cell lines. No correlation was found between the level of antigen expression and bi-specific MAb-mediated cytolysis.

Original languageEnglish
Pages (from-to)128-136
Number of pages9
JournalInternational Journal of Cancer
Volume55
Issue number1
Publication statusPublished - 1993

Fingerprint

Tumor-Associated Carbohydrate Antigens
Viral Tumor Antigens
T-Lymphocytes
Antibodies
Ovarian Neoplasms
Clone Cells
Ion Exchange
Staphylococcal Protein A
Hybridomas
Organism Cloning
Immunohistochemistry
High Pressure Liquid Chromatography
Lymphocytes
Carcinoma
Antigens
Cell Line
OC-TR monoclonal antibody
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. / Van Ravenswaay Claasen, H. H.; Van De Griend, R. J.; Mezzanzanica, D.; Bolhuis, R. L H; Warnaar, S. O.; Fleuren, G. J.

In: International Journal of Cancer, Vol. 55, No. 1, 1993, p. 128-136.

Research output: Contribution to journalArticle

Van Ravenswaay Claasen, H. H. ; Van De Griend, R. J. ; Mezzanzanica, D. ; Bolhuis, R. L H ; Warnaar, S. O. ; Fleuren, G. J. / Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. In: International Journal of Cancer. 1993 ; Vol. 55, No. 1. pp. 128-136.
@article{eebc20b8f2f544dc95979442866489b6,
title = "Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3",
abstract = "OV-TL 3 and MOv 18 MAbs, due to their restricted specificity, have been successfully used to visualize ovarian cancer in patients and might therefore be used to develop therapies for ovarian cancer. The bi-specific MAbs αT3/OC2 and αOC/TR (both being combinations of MOv 18 and αCD3) have been shown to lyse ovarian tumor cells in vitro. To evaluate the relative merits of MOv 18/CD3 and OV-TL 3/CD3, the present study was undertaken in which the bi-specific MAbs αT3/OC2 and αOC/TR, and a newly developed bi-specific MAb, OV-TL 3/CD3, were highly purified and compared for specificity, stability, purification and cytolytic potential. The dual specificity of the hybrid-hybridoma supernatants was analyzed by immunohistochemistry, and by testing bi-specific MAb-mediated cytotoxicity against relevant target cells in the presence of effector cells. Stability testing of bi-specific MAb-producing hybridhybridomas showed that, after sub-cloning, clones stably produced up to 40{\%} bi-specific MAb even after prolonged in vitro culture. The purification of the bi-specific fractions was performed with protein A and by ion-exchange high-pressure liquid chromatography, depending on the sub-class combination of the bi-specific MAb. The purified bi-specific MAbs were tested for their ability to mediate target-cell lysis with the use of cytotoxic T-cell clones and activated peripheral-blood lymphocytes. The purified αT3/OC2, αOC/TR, and OV-TL 3/CD3 were all able to mediate highly specific lysis of various ovarian-carcinoma cell lines. No correlation was found between the level of antigen expression and bi-specific MAb-mediated cytolysis.",
author = "{Van Ravenswaay Claasen}, {H. H.} and {Van De Griend}, {R. J.} and D. Mezzanzanica and Bolhuis, {R. L H} and Warnaar, {S. O.} and Fleuren, {G. J.}",
year = "1993",
language = "English",
volume = "55",
pages = "128--136",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3

AU - Van Ravenswaay Claasen, H. H.

AU - Van De Griend, R. J.

AU - Mezzanzanica, D.

AU - Bolhuis, R. L H

AU - Warnaar, S. O.

AU - Fleuren, G. J.

PY - 1993

Y1 - 1993

N2 - OV-TL 3 and MOv 18 MAbs, due to their restricted specificity, have been successfully used to visualize ovarian cancer in patients and might therefore be used to develop therapies for ovarian cancer. The bi-specific MAbs αT3/OC2 and αOC/TR (both being combinations of MOv 18 and αCD3) have been shown to lyse ovarian tumor cells in vitro. To evaluate the relative merits of MOv 18/CD3 and OV-TL 3/CD3, the present study was undertaken in which the bi-specific MAbs αT3/OC2 and αOC/TR, and a newly developed bi-specific MAb, OV-TL 3/CD3, were highly purified and compared for specificity, stability, purification and cytolytic potential. The dual specificity of the hybrid-hybridoma supernatants was analyzed by immunohistochemistry, and by testing bi-specific MAb-mediated cytotoxicity against relevant target cells in the presence of effector cells. Stability testing of bi-specific MAb-producing hybridhybridomas showed that, after sub-cloning, clones stably produced up to 40% bi-specific MAb even after prolonged in vitro culture. The purification of the bi-specific fractions was performed with protein A and by ion-exchange high-pressure liquid chromatography, depending on the sub-class combination of the bi-specific MAb. The purified bi-specific MAbs were tested for their ability to mediate target-cell lysis with the use of cytotoxic T-cell clones and activated peripheral-blood lymphocytes. The purified αT3/OC2, αOC/TR, and OV-TL 3/CD3 were all able to mediate highly specific lysis of various ovarian-carcinoma cell lines. No correlation was found between the level of antigen expression and bi-specific MAb-mediated cytolysis.

AB - OV-TL 3 and MOv 18 MAbs, due to their restricted specificity, have been successfully used to visualize ovarian cancer in patients and might therefore be used to develop therapies for ovarian cancer. The bi-specific MAbs αT3/OC2 and αOC/TR (both being combinations of MOv 18 and αCD3) have been shown to lyse ovarian tumor cells in vitro. To evaluate the relative merits of MOv 18/CD3 and OV-TL 3/CD3, the present study was undertaken in which the bi-specific MAbs αT3/OC2 and αOC/TR, and a newly developed bi-specific MAb, OV-TL 3/CD3, were highly purified and compared for specificity, stability, purification and cytolytic potential. The dual specificity of the hybrid-hybridoma supernatants was analyzed by immunohistochemistry, and by testing bi-specific MAb-mediated cytotoxicity against relevant target cells in the presence of effector cells. Stability testing of bi-specific MAb-producing hybridhybridomas showed that, after sub-cloning, clones stably produced up to 40% bi-specific MAb even after prolonged in vitro culture. The purification of the bi-specific fractions was performed with protein A and by ion-exchange high-pressure liquid chromatography, depending on the sub-class combination of the bi-specific MAb. The purified bi-specific MAbs were tested for their ability to mediate target-cell lysis with the use of cytotoxic T-cell clones and activated peripheral-blood lymphocytes. The purified αT3/OC2, αOC/TR, and OV-TL 3/CD3 were all able to mediate highly specific lysis of various ovarian-carcinoma cell lines. No correlation was found between the level of antigen expression and bi-specific MAb-mediated cytolysis.

UR - http://www.scopus.com/inward/record.url?scp=0027291202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027291202&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 128

EP - 136

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -